Celyad-Logo-Color.jpg
CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
May 05, 2022 18:12 ET | Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the...
Celyad-Logo-Color.jpg
Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
May 05, 2022 16:05 ET | Celyad Oncology SA
Enrollment continues in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM)Dialogue continues with...
Starton logo-pantone2112C.jpg
Starton Therapeutics Provides Update on STAR-LLD Lenalidomide Clinical Program
May 04, 2022 07:00 ET | Starton Therapeutics, Inc.
Independent safety review approved dose escalation and initiation of next dosing cohortSTAR-LLD generally well tolerated in all subjects dosed to dateOn track to complete dosing of all cohorts in May...
Starton logo-pantone2112C.jpg
Starton Therapeutics Announces Notice of Allowance for U.S. Patent Application Protecting Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents
October 04, 2021 07:00 ET | Starton Therapeutics, Inc.
PARAMUS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies, today...
Starton logo-pantone2112C.jpg
Starton Therapeutics Announces Successful Results in STAR-LLD Toxicology Study: No Myelosuppression and Excellent Tolerability
September 30, 2021 07:10 ET | Starton Therapeutics, Inc.
PARAMUS, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies,...
Logo.png
Multiple Myeloma Pipeline Analysis Demonstrates Stunning Growth With A Gamut of Pharma Companies Involved Worldwide 
May 18, 2021 20:20 ET | DelveInsight Business Research LLP
Los Angeles, USA, May 18, 2021 (GLOBE NEWSWIRE) -- Multiple Myeloma Pipeline Analysis Demonstrates Stunning Growth with a Gamut of Pharma Companies Involved Worldwide  The Multiple Myeloma...
Logo.png
Comprehensive Analysis of 250+ Key Companies Developing 250+ Novel CAR-T Therapies: DelveInsight 
April 20, 2021 20:50 ET | DelveInsight Business Research LLP
Los Angeles, USA, April 20, 2021 (GLOBE NEWSWIRE) -- Comprehensive Analysis of 250+ Key Companies Developing 250+ Novel CAR-T Therapies: DelveInsight  More than 50% of trials investigating...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple Myeloma
December 07, 2020 08:00 ET | TeneoBio, Inc
NEWARK, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, reported...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio Announces the Presentation of Interim Phase I Data on TNB-383B (Anti-BCMAxCD3) at the 62nd Annual Meeting of the American Society of Hematology
November 19, 2020 08:00 ET | TeneoBio, Inc
NEWARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Teneobio Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, today...
TELO-new LOGO.jpg
Telo Genomics Announces Study Results Showing That TeloView® Differentiates Between Stable Smoldering Multiple Myeloma Patients and Patients That Progressed to Active Multiple Myeloma
November 16, 2020 11:13 ET | Telo Genomics Corp.
TORONTO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce the positive results of its smoldering multiple myeloma proof of concept...